Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13236218 | 0.87 | ALDH1A1 (0.37) | ALDH1A1NPC1RAB9AGAAGFER | |
| SCHEMBL13236238 | 0.83 | MAPT (0.39) | ALDH1A1RAB9AGAA | |
| SCHEMBL13264578 | 0.81 | ALK (0.30) | GAA | |
| SCHEMBL13264544 | 0.81 | L3MBTL1 (0.32) | ALDH1A1NPC1RAB9AGAA | |
| SCHEMBL13236240 | 0.77 | PTGDR2 (0.47) | ALDH1A1NPC1RAB9A | |
| SCHEMBL13817751 | 0.75 | PTGDR2 (0.44) | ALDH1A1NPC1RAB9A | |
| SCHEMBL13264604 | 0.72 | TLR7 (0.36) | EGFRALDH1A1NPC1RAB9AGAA | |
| SCHEMBL13264545 | 0.72 | EGFR (0.37) | EGFRALDH1A1NPC1RAB9AGAA | |
| SCHEMBL13264579 | 0.72 | ALDH1A1 (0.39) | EGFRALDH1A1NPC1RAB9AGAA | |
| SCHEMBL13817752 | 0.71 | MAPT (0.36) | ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750014-B2 | Imidazo[1,2-C]pyrimidinylacetic acid derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | ACTIMIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012102-A1 | Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives | HRH2, CCR2, HRH1 | EGFR 1141/4885ALDH1A1 1532/4885NPC1 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.